Unlocking 
Tomorrow's Heartcare, Today.

Our Vision

We are dedicated to transforming challenges into opportunities. Cuspa™ safeguards choices for future aortic disease treatments by looking beyond current issues and preserving options for tomorrow’s care.

We firmly believe in a holistic approach, assessing not just today’s problems but also foreseeing and addressing those that may emerge in the future.
Cusper™ Preserving Future Choices, AR Repair Today.
Tomorrow, All Options Remain Open.

Cusper™ Device Preserving Future Choices


AR Repair Today.

Tomorrow, All Options Remain Open.

Cusper™ Preserving Future Choices


AR Repair Today.
Tomorrow, All Options Remain Open.

The Need

1 in 8 people over 75 years old suffer from valvular heart disease (VHD), while aortic regurgitation is the third most common VHD. Patients suffering from moderate to severe aortic regurgitation (AR) face a notable absence of minimally invasive repair options, underscoring a significant gap in the provision of medical care.

Aortic Stenosis

Narrowing of the aortic valve opening and restricting the amount of blood flowing through

Aortic Regurgitation 

Leakage of blood through the aortic valve each time the left ventricle relaxes (diastole)

Aortic Stenosis

Narrowing of the aortic valve opening and restricting the amount of blood flowing through

Aortic Regurgitation 

Leakage of blood through the aortic valve each time the left ventricle relaxes (diastole)

Current Treatment and Challenges:

Currently, treatment options for aortic regurgitation (AR) are limited. While transcatheter aortic valve implantation (TAVI) addresses severe aortic stenosis by relying on calcification for anchoring, it faces challenges. AR cases are often absence calcification, necessitating surgical aortic valve replacement, which carries risks such as serious complications, prolonged hospital stays, and long recovery. In addition, TAVI is not approved for patients with severe native aortic valve regurgitation.

The Solution

Cusper™ device a Transcatheter Aortic Valve Repair

The first seamless integration repair device for Aortic Valve Regurgitation

Open AV 

While Cusper™ device clipped

Close AV 

While Cusper™ device clipped

An artificial cusp seamlessly merges with the native aortic valve and prevents backward blood flow into the left ventricle during diastole, ensuring comprehensive and effective repair.

The Cusper™ device offers a unique solution that preserves future choices by enabling AR repair today while allowing flexibility for transcatheter aortic valve implantation options in the future, ensuring that all options remain open.
Proximal Distal
Pericardium Sac
point
Nitinol Frame
point
Grasping Arm
point

Cusper™ Device Reduces Aortic Regurgitation

Aortic Regurgitation
without Cusper™ device.

Aortic Regurgitation 
with Cusper™ device.

The Team

Meet the Innovators behind Cuspa™

Elad Sapir, CEO

Executive with over 20 years of experience in the Medtech sector as CEO, VP, and R&D leader at Transseptal Solutions, Expanding Orthopedics, and Remon Medical Technologies. Holds a BSc in Mechanical Engineering from Ben Gurion University of the Negev.

Dr. Yair Feld, Founder

MD, PhD, interventional cardiologist, 15+ years of experience. Founder of Corassist, Nephera, Paragate Medical, ProArc, Cuspa, and Genegrafts.

Zohar Gendler, Chairman of the board

CEO & Managing Partner of NGT3 VC. Led establishment of and investment in more than 50 companies such as Prolor Biotech (sold to OPKO for $480M), Mazor Robotics (sold to Medtronic for $1.6B), ReWalk (NASDAQ: RWLK), and Corindus (sold to Siemens Healthcare for $1.1B).

News & Events

Explore our achievements and upcoming events

Stay connected: Follow us for updates and insights

Linkedin Youtube Envelope

Write us

info@cuspamedical.com
Terms of Service